CASI Pharmaceuticals, Inc. Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

CASI Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing CID-103 for organ transplant rejection and autoimmune diseases. CID-103 is an anti-CD38 monoclonal antibody being evaluated in a Phase 1 dose-ranging and safety study to assess tolerability and efficacy in adults with active and chronic active renal allograft antibody mediated rejection. The company announced FDA clearance of an IND for CID-103, enabling the early clinical program. 

In December 2025, CID-103 data from a Phase 1 open-label study in immune thrombocytopenia were presented at the American Society of Hematology Annual Meeting, illustrating clinical evaluation of the antibody in additional conditions. The company has pursued governance updates, including independent director appointments in 2025 and leadership changes in 2026, reflecting organizational evolution as it advances its CID-103 program.

Sign up for free to view info

Company overview Employee directory